> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Medpace Holds Back 2027 Guidance Until February, Says Cancellations Are The Swing Factor
- URL: https://www.bullished.co/medpace-holds-back-2027-guidance-until-february-says-cancellations-are-the-swing-factor-9716f8ac/
- Published: 2026-10-22T14:06:01.000Z
- Updated: 2026-10-29T19:08:08.000Z
- Description: The trial-services firm posted record new awards but would not give a 2027 outlook, citing cancellations and a $20 million Cincinnati cost.
- Author: Matteo Parrino
- Tags: Earnings, MEDP, Industry: Healthcare

[Medpace](https://www.bullished.co/tag/medp/), which runs drug and device trials for biotech and pharmaceutical companies, will not give a 2027 outlook until its fourth-quarter report in February, CEO August Troendle said on the company's earnings call Thursday. He added that "we see no large disconnect between analyst consensus estimates and our current modeling of 2027," according to the [call transcript](https://www.benzinga.com/news/26/10/62527662/medpace-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co).

## Why Medpace is waiting

Pressed by an analyst at Deutsche Bank on why the company changed course from last year, Troendle said management's view of 2027 has moved over the last quarter and should keep moving. "There's no point in making a poor guide that might not be very accurate in retrospect," he said.

He named fourth-quarter cancellations as the key variable. Awards in the quarter still matter for next year's revenue, he said, but "more importantly" the cancellation pattern does. Cancellations this quarter were "a little bit higher than we would have liked" but manageable, he said, and he described them as mainly product failures, including safety signals, rather than a funding problem.

An analyst at Mizuho noted that implied 2027 growth looks lower than Medpace's usual pace. Troendle said the growth profile has dropped over the last few years, mainly from cancellation pressure, while revenue expectations for 2027 are improving month to month.

## A $20 million Cincinnati cost

CFO Kevin Brady said consensus looks reasonable against the company's own modeling. He added that a significant expansion coming online in Cincinnati will add about [$20 million of operating costs](https://www.benzinga.com/news/26/10/62527662/medpace-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co) in 2027.

The board also approved a new share repurchase authorization of up to $1 billion, effective October 20, replacing the prior one. Brady said 2026 guidance assumes no additional purchases.

## Record awards, 8.5% revenue growth

Third-quarter revenue was [$716 million](https://www.benzinga.com/news/26/10/62527662/medpace-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co), up 8.5% from a year earlier. Net income rose 23.7% to $137.5 million, or $4.84 per diluted share. EBITDA was $172.1 million, up 16%, with a 24% margin.

Net new business awards hit an all-time high at $873.4 million, up 10.6%, and ending backlog was about $3.2 billion, up 5.6%. Medpace expects about $1.99 billion of that backlog to convert to revenue in the next 12 months.

Full-year 2026 revenue is now guided to $2.835 billion to $2.855 billion, or 12% to 12.8% growth, with earnings of $17.97 to $18.32 per diluted share.

The fourth-quarter report in February brings the first formal 2027 guidance, and Troendle said it will turn on whether cancellations stay in range.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Medpace Hldgs Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62527662/medpace-hldgs-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates](https://finance.yahoo.com/markets/stocks/articles/medpace-medp-q3-earnings-revenues-205006108.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations](https://finance.yahoo.com/markets/stocks/articles/medpace-nasdaq-medp-reports-q3-202845938.html?ref=bullished.co) — Yahoo Finance
- [Medpace beats Q3 estimates but guides below on revenue](https://finance.yahoo.com/markets/stocks/articles/medpace-beats-q3-estimates-guides-213305631.html?ref=bullished.co) — Yahoo Finance
- [Medpace Stock Slips Despite Third-Quarter Beat, Solid Earnings Outlook | Investor's Business Daily](https://www.investors.com/news/technology/medpace-stock-medpace-holdings-earnings-q3-2026/?ref=bullished.co) — investors.com

### More on Medpace Holdings

- [Medpace's Three Book-To-Bill Shareholder Suits Are Dropped, Then A $1 Billion Buyback Is Approved](https://www.bullished.co/medpaces-three-book-to-bill-shareholder-suits-are-dropped-then-a-1-billion-buyback-is-3337443a/)
- [Medpace Third-Quarter Net Income Rises To $137.5 Million, And Board Approves New Buyback](https://www.bullished.co/medpace-third-quarter-net-income-rises-to-137-5-million-and-board-approves-new-buyback-a11f8e9f/)
- [Medpace CEO August Troendle Sells $30.3 Million In MEDP Stock, Pushing September Total Past $125 Million](https://www.bullished.co/medpace-ceo-august-troendle-sells-30-3-million-in-medp-stock-pushing-september-total-past-e4fb87fc/)

[All Medpace Holdings (MEDP) coverage →](https://www.bullished.co/tag/medp/)